Vor Ort
Merkzettel Warenkorb
  • Produktbild: Early Diagnosis and Preventive Therapy in Parkinson's Disease
  • Produktbild: Early Diagnosis and Preventive Therapy in Parkinson's Disease

Early Diagnosis and Preventive Therapy in Parkinson's Disease

Aus der Reihe Key Topics in Brain Research

48,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

30.12.1988

Herausgeber

Horst Przuntek + weitere

Verlag

Springer Wien

Seitenzahl

447

Maße (L/B/H)

22,9/15,2/2,4 cm

Gewicht

667 g

Sprache

Englisch

ISBN

978-3-211-82080-3

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

30.12.1988

Herausgeber

Verlag

Springer Wien

Seitenzahl

447

Maße (L/B/H)

22,9/15,2/2,4 cm

Gewicht

667 g

Sprache

Englisch

ISBN

978-3-211-82080-3

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Ein neues Kapitel für Ihre Bücher

Ein neues Kapitel für Ihre Bücher

Schenken Sie Ihren alten Schätzen ein zweites Leben und erhalten dafür eine Thalia Geschenkkarte.

Jetzt verkaufen
Jetzt verkaufen

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Early Diagnosis and Preventive Therapy in Parkinson's Disease
  • Produktbild: Early Diagnosis and Preventive Therapy in Parkinson's Disease
  • The premorbid personality of patients with Parkinson’s disease.- Parkinson’s disease: development of dementia in aging.- Psychometric assessment of early signs of dementia in special consideration of Parkinson’s and Alzheimer’s disease — an update.- Sensory and musculo-skeletal dysfunction in Parkinson’s disease—premonitory and permanent.- Autonomic nervous system screening in patients with early Parkinson’s disease.- Clinical and biochemical characteristics of early depression in Parkinson’s disease.- Psychomotor investigations in depressed patients by comparison with Parkinson patients.- Quantitative analysis of voluntary and involuntary motor phenomena in Parkinson’s disease.- Motor performance test.- Measuring body movements in neurological disease, with special reference to Parkinson’s disease.- Long-term measurement of tremor: early diagnostic possibilities.- Tremor and electrically elicited long-latency reflexes in early stages of Parkinson’s disease.- Evoked potentials in Parkinson’s disease.- Brain mapping of EEG and evoked potentials during physiological aging and in Parkinson’s disease, dementia and depression.- Positron emission tomography in Parkinson’s disease glucose metabolism.- Parkinson’s disease studied using PET.- Pathobiochemistry of the extrapyramidal system: a “short note” review.- Dopaminergic neurotransmission and status of brain iron.- Dopaminergic modulation of neuropeptide gene expression in the rat striatum.- The diagnostic relevance of Lewy bodies and other inclusions in Parkinson’s disease.- Cytoskeletal pathology of the Lewy bodies.- Plasma concentrations of endogenous DOPA and 3-O-methyl-DOPA in rats administered benserazide and carbidopa alone or in combination with the reversible COMT inhibitor Ro41-0960.- Catecholamines in urine, blood and cerebrospinal fluid.- 3H-spiperone binding to lymphocytes is increased in schizophrenic patients and decreased in parkinson patients.- Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro19-6327.- Aspartate, glutamate, and glutamine in platelets of patients with Parkinson’s disease.- Hypothalamic dysfunction and neuroendocrine research in Parkinson’s disease.- The MPTP model: an update.- Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease?.- Importance of dopaminergic and GABAergic neurones of the nucleus accumbens and the caudate nucleus for motoricity.- Is D-1 receptor stimulation important for the anti-parkinson activity of dopamine agonists?.- Pharmacological and clinical-pharmacological aspects of D1- and D2-receptors.- Chemical modulation of membrane-bound receptors.- Transplantation of dopamine-synthesizing cells — new therapy for Parkinson’s disease?.- L-dopa in Parkinson’s disease.- Pharmacokinetic investigations of various levodopa formulations.- Iron therapy in Parkinson’s disease. Stimulation of endogenous presynaptic L-DOPA biosynthesis by the iron compound oxyferriscorbone.- Provisional experiences with the combination of L-dopa and L-deprenyl.- Clinical pharmacology of amantadine and derivatives.- Dopamine agonist treatment in early Parkinson’s disease.- Subcutaneous apomorphine in Parkinson’s disease.- Continuous dopaminergic stimulation with parenteral lisuride in complicated Parkinson’s disease.- Discussion.